Samsung Biologics and LegoChem Biosciences Forge Strategic Partnership for ADC Development and Manufacturing

12 February 2024 | Monday | News

In a significant move poised to propel advancements in oncology treatment, Samsung Biologics (KRX: 207940.KS), a leading global contract development and manufacturing organization (CDMO), has announced a groundbreaking partnership with LegoChem Biosciences (KOSDAQ: 141080), a trailblazing biotech enterprise specializing in antibody-drug conjugate (ADC) programs.
Image Source : Public Domain

Image Source : Public Domain


The collaboration marks a pivotal milestone as Samsung Biologics commits to providing cutting-edge antibody development and drug substance manufacturing services in support of LegoChem Biosciences' ADC initiative targeting solid tumors. This venture underscores a shared commitment to accelerate therapeutic innovations for patients in need.

With plans to submit an Investigational New Drug application to the U.S. FDA by the first half of 2025, LegoChem Biosciences anticipates leveraging Samsung Biologics' expertise to propel its ADC program forward, backed by promising non-clinical efficacy data.

The partnership aligns seamlessly with Samsung Biologics' ongoing expansion efforts, as it prepares to unveil a dedicated ADC facility later this year. This strategic investment reinforces the company's commitment to bolstering its capabilities and spearheading advancements within the burgeoning ADC landscape.

John Rim, CEO and President of Samsung Biologics, expressed enthusiasm about the collaboration, stating, "Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients." He further emphasized the shared vision to unlock new opportunities in the dynamic ADC domain.

Echoing this sentiment, Yong-Zu Kim, CEO and President of LegoChem Biosciences, highlighted the strategic significance of securing a stable domestic supply chain through the partnership. He noted, "LegoChem Biosciences had previously supplied antibodies for ADC through only overseas companies, but we expect that we will be able to secure a stable domestic supply chain through this contract."

Samsung Biologics is poised to leverage its extensive capabilities in ADC development and manufacturing, leveraging its proficiency in antibody engineering, process development, and large-scale antibody manufacturing. The company's strategic investments, including those facilitated through the Samsung Life Science Fund, further underscore its commitment to driving innovation and advancing ADC technologies.

As the partnership between Samsung Biologics and LegoChem Biosciences unfolds, it promises to catalyze transformative breakthroughs in the realm of oncology therapeutics, offering renewed hope for patients worldwide.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in